Bioindustrial Division, Influenza Production Laboratory, Instituto/Fundação Butantan, São Paulo, Brazil.
Vaccine. 2011 Jul 1;29 Suppl 1:A12-5. doi: 10.1016/j.vaccine.2011.04.127.
Technology transfer is a promising approach to increase vaccine production at an affordable price in developing countries. In the case of influenza, it is imperative that developing countries acquire the technology to produce pandemic vaccines through the transfer of know-how, as this will be the only way for the majority of these countries to face the huge demand for vaccine created by influenza pandemics. Access to domestically produced influenza vaccine in such health crises is thus an important national defence strategy. However, technology transfer is not a simple undertaking. It requires a committed provider who is willing to transfer a complete production process, and not just the formulation and fill-finish parts of the process. It requires a recipient with established experience in vaccine production for human use and the ability to conduct research into new developments. In addition, the country of the recipient should preferably have sufficient financial resources to support the undertaking, and an internal market for the new vaccine. Technology transfer should create a solid partnership that results in the joint development of new competency, improvements to the product, and to further innovation. The Instituto Butantan-sanofi pasteur partnership can be seen as a model for successful technology transfer and has led to the technological independence of the Instituto Butantan in the use a strategic public health tool.
技术转让是一种有前途的方法，可以以负担得起的价格在发展中国家增加疫苗产量。在流感的情况下，发展中国家必须通过技术转让获得生产大流行性疫苗的技术，因为这将是大多数国家应对流感大流行所带来的巨大疫苗需求的唯一途径。在这种卫生危机中获得国产流感疫苗是一项重要的国防战略。然而，技术转让并非易事。它需要一个有意愿转让完整生产过程的承诺方，而不仅仅是转让该过程的配方和灌装部分。它需要一个在人用疫苗生产方面具有成熟经验并能够进行新发展研究的接收方。此外，接收方的国家最好有足够的财政资源来支持这项工作，并具有新疫苗的内部市场。技术转让应建立一个坚实的伙伴关系，从而共同开发新的能力、改进产品并进一步创新。布坦坦研究所-赛诺菲巴斯德的合作关系可以被视为成功技术转让的典范，并且已经使布坦坦研究所能够在使用这一战略公共卫生工具方面实现技术独立。
